Publication:
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

No Thumbnail Available
Date
2021-02-13T00:00:00Z
Authors
Sezer, Ahmet
Kilickap, Saadettin
Gümüş, Mahmut
Bondarenko, Igor
Özgüroğlu, Mustafa
Gogishvili, Miranda
Turk, HACI MEHMET
Cicin, Irfan
Bentsion, Dmitry
Gladkov, Oleg
Journal Title
Journal ISSN
Volume Title
Publisher
Research Projects
Organizational Units
Journal Issue

Metrics

Search on Google Scholar

Abstract
Description
Keywords
Citation
Sezer A., Kilickap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.-, Lancet (London, England), cilt.397, ss.592-604, 2021
Page Views

0

File Downloads

0

Sustainable Development Goals